Techno Trends
Worldwide advancements and breakthroughs in pharmaceutical products and technology are thoroughly covered by Techno Trends. You may stay up to date with all the most recent pharmaceutical developments (product news and technological trends) taking place throughout the world.
HUTCHMED Achieves Breakthrough Therapy Designation for Savolitinib's Potential in Treating Gastric Cancer
HUTCHMED has announced a significant milestone in the field of gastric cancer treatment. The Center for Drug Evaluation under China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to savolitinib....
Artiva Biotherapeutics Secures FDA Nod for AlloNK® Cell Therapy alongside Rituximab in Lupus Nephritis Treatment
Artiva Biotherapeutics, a clinical-stage company with a focus on delivering highly effective, off-the-shelf allogeneic natural killer (NK) cell-based therapies, has received FDA clearance for its Investigational New Drug (IND) application concerning AlloNK® (also known as AB-101)....
Novel Compounds Combat Viruses by Disrupting Their Envelope Structures
Researchers explored seven different peptoids with the aim of targeting virus membranes rather than their proteins. This innovative approach could usher in a new era of antiviral drugs....
Jacobio Pharma Secures Breakthrough Designation for Glecirasib a Pancreatic Cancer Drug
Jacobio Pharma, a company dedicated to advancing oncology treatments, has revealed a significant development. Their internally developed KRAS G12C inhibitor, named glecirasib, has received the coveted breakthrough therapy designation (BTD) from China's Center for Drug Evaluation (CDE), a division of the National Medical Products Administration (NMPA). This designation is intended for pancreatic cancer patients with a specific KRAS G12C mutation who have not responded to standard initial treatments....
FDA Grants Extended Breakthrough Therapy Designation to NS-089/NCNP-02 for Duchenne Muscular Dystrophy
NS Pharma's recent announcement highlights the regulatory acknowledgment by the U.S. Food and Drug Administration, underscoring the significance of their investigational candidate, NS089/NCNP-02. This designation is intended for patients who have Duchenne muscular dystrophy amenable to exon 44 skipping therapy....
FDA Grants Breakthrough Therapy Designation to Renibus Therapeutics' RBT-1 for Cardiothoracic Surgery Complications
Renibus Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the prevention and treatment of cardio-renal diseases, recently made an announcement regarding the Breakthrough Therapy designation granted to their drug candidate, RBT-1...
T2 Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Detection Test T2
T2 Biosystems, Inc. is a leading company specializing in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes....
Recbio's Novel Adjuvanted Shingles Vaccine Accepted for Clinical Trial in China
Jiangsu Recbio Technology Co., Ltd. is excited to announce that their research project has achieved a significant milestone. The National Medical Products Administration (NMPA) has accepted the Company's clinical trial application for their innovative adjuvanted recombinant shingles vaccine, REC610. ...
MyoPax's breakthrough regenerative cell product for Exstrophy-Epispadias Complex earns Rare Pediatric Disease Designation
The U.S. Food and Drug Administration (FDA) has granted MyoPax, a young European biotech start-up, a Rare Pediatric Disease Designation (RPDD) for their innovative regenerative cell therapies. MyoPax focuses on developing treatments for debilitating muscle disorders...
FDA Approves Skyline Therapeutics' Novel Gene Therapy for Macular Degeneration
Skyline Therapeutics, a company focused on developing solutions for rare and severe diseases, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application....
